EUVIMEDEUVIMED entdecken
Vergleichsstudie

Secukinumab versus conventional immunotherapy in myasthenia gravis: A single-Center 24-week retrospective comparative study

Shuangmei Zhang, Anrong Wang, Xiaodong Song, Zhaoxu Zhang

International Immunopharmacology · 2026

DOI: 10.1016/j.intimp.2026.116175 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Shuangmei Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Rehabilitation, Zhejiang Cancer Hospital, Hangzhou 310022, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Antibodies, Monoclonal, Humanized, Immunotherapy, Immunosuppressive Agents. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Key Technology Research and Development Program of Shandong Province, Shandong First Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Myasthenia gravis (MG) management remains challenged by the delayed onset of conventional immunosuppressants. While B-cell and complement pathways are established therapeutic targets, the role of IL-17 A in human MG is underexplored, and its potential as a target represents a novel therapeutic avenue. OBJECTIVES: This study aimed to evaluate, for the first time in a clinical setting, the efficacy and safety of the anti-IL-17 A monoclonal antibody secukinumab compared to conventional immunotherapy in patients with acetylcholine receptor-positive generalized MG (AChR+ gMG). METHODS: In this single-center, retrospective cohort study, 35 patients received subcutaneous secukinumab (150 mg/week for 4 weeks, then monthly) plus standard care, while 32 matched controls received conventional immunosuppressants alone. Outcomes included clinical scores (QMG, MG-ADL, MG-QOL15), AChR antibody (AChR-Ab) titers, and immunologic parameters (Th17/Tfh cells, cytokines) assessed at baseline, week 4, 12, and 24. RESULTS: Secukinumab demonstrated significantly superior and rapid efficacy. By week 24, improvement rates in QMG, MG-ADL, and MG-QOL15 scores were significantly greater with secukinumab (44.7%, 45.7%, 46.7%) than controls (27.5%, 25.8%, 32.0%; all p < 0.01). AChR-Ab levels decreased rapidly by 61.1% as early as week 4, achieving a 68.9% reduction at week 24, significantly surpassing the control group's response (21.6%). Immunologically, secukinumab induced rapid and profound suppression of IL-17 A (-84.1% at week 4), Th17 cells (-68.3%), and Tfh cells (-71.7%) over 24 weeks, effects strongly correlated with each other and with AChR-Ab decline. Reductions in key cytokines (IL-6, IL-21) were also more pronounced. CONCLUSION: This first clinical investigation of IL-17 A inhibition in AChR+ gMG demonstrates that secukinumab provides rapid, superior clinical and serological efficacy alongside broad immunomodulation, targeting the Th17/Tfh-B cell axis.Further prospective studies are needed to validate these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAntibodies, Monoclonal, HumanizedImmunotherapyImmunosuppressive AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultInterleukin-17Th17 CellsTreatment OutcomeReceptors, CholinergicAgedCytokines

Stichwörter der Autor:innen

AChRIL-17Myasthenia gravisSecukinumabTh17

Substanzen

Antibodies, Monoclonal, HumanizedsecukinumabInterleukin-17Receptors, CholinergicImmunosuppressive AgentsCytokines

Autor:innen und Institutionen

  • Department of Pain Rehabilitation, Zhejiang Cancer Hospital, Hangzhou 310022, China.
  • The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 251412, China.
  • Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Neurology, Peking University People's Hospital, Beijing 100044, China. Electronic address: zhangzhaoxu55@163.com.

Förderung

  • Key Technology Research and Development Program of Shandong Province
  • Shandong First Medical University
  • National Natural Science Foundation of China
  • Medical Science and Technology Project of Zhejiang Province

Zitieren

APA

Zhang, S., Wang, A., Song, X., & Zhang, Z. (2026). Secukinumab versus conventional immunotherapy in myasthenia gravis: A single-Center 24-week retrospective comparative study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116175

Vancouver

Zhang S, Wang A, Song X, Zhang Z. Secukinumab versus conventional immunotherapy in myasthenia gravis: A single-Center 24-week retrospective comparative study. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116175

BibTeX
@article{Zhang2026,
  author = {Zhang, Shuangmei and Wang, Anrong and Song, Xiaodong and Zhang, Zhaoxu},
  title = {Secukinumab versus conventional immunotherapy in myasthenia gravis: A single-Center 24-week retrospective comparative study},
  journal = {International Immunopharmacology},
  year = {2026},
  doi = {10.1016/j.intimp.2026.116175}
}
Kostenlos starten →